Abstract 498P
Background
Frailty is of importance for older lung cancer patients, but the remaining lifetime is still not estimated for frailty but solely relied on cancer stage or cell type. In this study, we aimed to estimate survival and life expectancy of older non-small cell lung cancer patients (NSCLC) by frailty status, using electronic-health records.
Methods
We retrospectively analyzed 4260 patients aged between 65 and 95 who were newly diagnosed with NSCLC in 2007-2018 in National Cancer Center, Korea and followed up until December 2020. Frailty was measured by laboratory tests before initial treatment (FI-Lab), then classified into non-frail (score <0.25) and frail groups (score>0.25). Kaplan-Meier curves and log-rank test were used to compare survival probabilities by frailty. Cox proportional hazard model were used to estimate effect of frailty on all-cause mortality, adjusted for age, sex and SEER stage. We also estimate average life expectancy by frailty for all patients and stratified by SEER stage.
Results
There were 1063 (25%) patients identified as being frail. Frail patients had a significantly poorer survival than the non-frail in total population, and in SEER stage groups. Overall, frailty is significantly associated with all-cause mortality (aHR: 1.65, 95% CI: 1.52-1.78). Average life expectancies of frail older patients were 7.75 (95% CI 6.48-9.27) years for localized stage, 3.55 (95% CI 3.05-4.08) years for regional stage and 0.89 (95% CI 0.78-1.02) years for distant stage. While these figures for non-frail patients diagnosed in same cancer stage were 10.05 (95% CI 9.49-11.38), 4.99 (95% CI 4.67-5.32), 1.94 (95%CI 1.82-2.06) respectively.
Conclusions
Survival and life expectancy of older NSCLC patients vary by frailty status. In clinical settings, frailty can be simply assessed by laboratory tests to provide more precise estimates of remaining life-year and help oncologists to better plan for treatment decision and follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Cancer Center Grant (No. NCC-2210880-2, NCC-2310450-1). In addition, one of the authors, Minh Thao Tu was supported by the “International Cooperation & Education Program” (NCCRI·NCCI 52210-52211, 2023)” of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract